# Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy

> **NCT05979220** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shuangyue Liu** · enrollment: 178 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib combined with Letrozole

## Key facts

- **NCT ID:** NCT05979220
- **Lead sponsor:** Shuangyue Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2023-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05979220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05979220, "Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05979220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*